Morgan Stanley Myovant Sciences Ltd. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.03 - $27.02 $7.84 Million - $8.81 Million	326,188 Added 241.85%	461,060 $12.4 Million
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $1.4 Million - $2.47 Million	-120,927 Reduced 47.27%	134,872 $2.42 Million
Q2 2022 Oct 27, 2022	SELL	$7.78 - $14.69 $1.75 Million - $3.3 Million	-224,877 Reduced 46.78%	255,799 $3.18 Million
Q2 2022 Aug 15, 2022	SELL	$7.78 - $14.69 $1.75 Million - $3.3 Million	-224,877 Reduced 46.78%	255,799 $3.18 Million
Q1 2022 Oct 27, 2022	BUY	$11.38 - $16.4 $2.56 Million - $3.69 Million	224,877 Added 87.91%	480,676 $6.4 Million
Q1 2022 May 13, 2022	BUY	$11.38 - $16.4 $1.53 Million - $2.2 Million	134,274 Added 38.76%	480,676 $6.4 Million
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $3.6 Million - $6 Million	251,444 Added 264.79%	346,402 $5.39 Million
Q3 2021 Nov 15, 2021	BUY	$18.94 - $26.99 $1.8 Million - $2.56 Million	94,958 New	94,958 $2.13 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.